Background: In the fields of traumatology and orthopaedics staphylococci are the most frequently isolated pathogens. Staphylococcus aureus and Staphylococcus epidermidis are known to be the major causative agents of osteomyelitis. The increasing number of multiresistant Staphylococcus aureus and resistant coagulase-negative staphylococci as a trigger of complicated osteomyelitis and implant-associated infections is a major problem. Antibiotic therapy fails in 20% of cases. Therefore the development of novel antibiotics becomes necessary.
Background
Osteomyelitis is an inflammatory process caused by infective microorganism [1] . With a percentage of 80% [2] S. aureus (Staphylococcus aureus) is the most common pathogen of osteomyelitis [1, 3] . Implant-associated infections are also often caused by S. epidermidis (Staphylococcus epidermidis) [3, 4] and occur with a rate from 3-33% [5] . The therapy of osteomyelitis still represents a major challenge [3] . A single antibiotic agent is the standard therapy for osteomyelitis in its early stages [1] . In order to cure the chronic stages of this bone infection a combined therapy has to be chosen, which consists of a combination of two antibiotic substances and the surgical approach, which implies the surgical debridement, the implant removal or the two-step replacement [1, 3, 6, 7] . The combination of rifampicin plus another antibiotic agent shows efficient therapeutic results for the implant-associated infection caused by S. aureus [1] . However, antibiotic therapy fails in 20% of cases. This might be explained by the ability of S. aureus to invade human osteoblast cells [1] [2] [3] and to survive intracellularly [1, 2] . Thereby, S. aureus can change its phenotype into SCVs (small colony variants), which is a bacterial subpopulation that is well adapted for long-term intracellular persistence [3, 8] . In general SCVs have a reduced metabolism and have an increased resistance against antibiotics, especially against aminoglycosides [3, 8, 9] . Furthermore, S. aureus and S. epidermidis can adhere to foreign material surfaces and form biofilm [1, 3, 7, 10, 11] . The bacterial biofilm is a matrix out of polysaccharides and proteins [10] and acts as a diffusion barrier that inhibits the diagnosis and eradication of bacteria [7] . PMMA (polymethylmetacrylate)-bone cement loaded with antibiotic substances is an established treatment for infected endoprotheses for over 40years with good longterm results [6, 12] . Antibiotic-loaded bone cement works as a local antibiotic-carrier with the function of a drug-delivery-system to achieve high antibiotic levels locally [12] [13] [14] and to decrease the infection rate [12] . PMMA-bone cement is most commonly loaded with aminoglycosides [15] , especially with gentamicin as a good prophylaxis as well as a treatment for implantassociated infections [16] . It was shown that PMMAbone cement loaded with gentamicin inhibits 80% of S. aureus-biofilm synthesis [17] . Despite these options the treatment of osteomyelitis remains a challenging problem [3] . MRSA-and VRSA-infections are increasing as well as the number of antibiotic-resistant S. aureus and S. epidermidis [3, 12] . Because of increasing resistance against gentamicin [12, 18] and vancomycin [18] new [16] or combined [12] antibiotics have to be added to bone cement. Furthermore 41% of clinical isolated S. aureus are resistant against gentamicin [16] . S. aureus also has the ability to grow on bone cement loaded with gentamicin [19] . S. epidermidis is able to adhere to bone cement in vivo [20] and in vitro and to synthesize biofilm on bone cement loaded with gentamicin [21] . Multiresistant pathogens are a major therapeutic problem [22] . Therefore new antibiotics are essential to minimize pathogens and to optimize the therapy of osteomyelitis [23] . In this context tigecyclin has been developed [24] , which is the first antibiotic of the glycylines with efficacy against many important pathogens, multiresistant strains, mixed infections and problematic pathogens [23, 24] . In clinical daily routine tigecyclin shows good therapeutic efficacy against intraabdominal infection, skin-and soft-tissue infections [23, 24] . Tigecyclin shows activity against infection caused by MRSA [25] and against biofilm associated pathogens [26] . Furthermore tigecyclin is absorbed by bone tissue after intravenous application [27] . Till 2007 only few tigecyclin-resistant S. aureus-strains were known [28] , there are even some rifampicin-resistant S. epidermidisstrains that were sensitive against tigecyclin [4] . This study investigates tigecyclin as a potential therapy for osteomyelitis caused by multiresistant S. aureus. Its intracellular activity is determined in comparison to gentamicin and rifampicin by a human osteoblast infection model [29] . The potential use in PMMA-bone cement is conducted concerning the ISO 5833-guidelines compared to gentamicin (International Organization for Standardization: Implants for surgery -Acrylic resin cements. 2002).
Methods

Human osteoblast infection model
To determine the intracellular activity of tigecyclin a primary human osteoblast model modified by HaslingerLoeffler et al. [29] is established. Due to the capacity of S. aureus to enter the intracellular environment two different S. aureus-strains (S. aureus Cowan I ATCC 12598, S. aureus Subspezies Rosenbach ATCC 49230) with different invasion characteristics (Cowan I: 100%, ATCC 49230: 180%) are used. S. carnosus TM 300 allegorizes the negative control without capacity to enter the intracellular environment. On the previous day of the assay the human osteoblast cells are seeded together with 1ml growth medium into 12-well tissue culture plates with a number of 1×10 5 /well. The growth medium consists of Minimum Essential Medium (MEM), HAM's F12 (MEM:HAM's F12 = 1:1), 10% fetal calf serum (FCS), penicillin/streptomycin (penicillin 100 Units/ml, streptomycin 100 mg/ml), 10nM Dexamethason, 0,2 mML-Ascorbat-2-Phosphate and 10 mM b-Glycerolphosphate. Prior to the investigation the bacteria strains have to be grown overnight. Bacterial cell numbers are measured spectrophotometrically at 540 nm and diluted with 1ml phosphate-buffered saline, pH7.4 (PBS) and with 1% HSA to ensure a cell number of 5×10 8 bacteria/ml. At the beginning of the assay the confluent grown osteoblast cells are washed with MEM/ HAM's F12 (1:1) and then incubated with the cultured bacteria and 1ml assay medium, which consists of MEM/ HAM's F12 (1:1) and 1% HSA, for 30 min at ambient temperature followed by 3h at 37°C and 5% CO 2 . In order to assure a multiplicity of infection (MOI) of 100 with an optical density (OD) of 1, bacteria are added with the following amounts: S. carnosus TM 300: 38 μl, S. aureus Cowan I ATCC 12598: 19 μl, S. aureus Subspezies Rosenbach ATCC 49230: 16 μl. After incubation the external S. aureus are inactivated by 20 mg/ml lysostaphin. Then 1ml MEM/HAM's F12 (1:1) + 10% FCS is added to the osteoblast cells with the intracellular persisting bacteria. For the following incubation for 20h or 40h at 37°C and 5% CO 2 10 μg/ml tigecyclin, 10 μg/ml gentamicin, 7 μg/ml rifampicin or the combinations tigecyclin/ gentamicin or tigecyclin/rifampicin are added. The antibiotic concentrations were chosen according to high level doses that can be reached after intravenous application in serum and tissue [31] [32] [33] . Both S. aureus strains were tested sensitive to the antibiotics tigecyclin, gentamicin and rifampicin (Table 1) 
Statistical analysis
Statistical analysis was performed with the Mann-Whithey-U-test for the results of the infection model. The results of the biomechanical testings besides the bending modulus were statically analysed by the unpaired t-test. Statistical analysis for the bending modulus was performed by the unpaired t-test with Welch correction. A value of * p ≤ 0.05 was consideres siginificant in all cases. 
Results
Human osteoblast infection model
Biomechanics
The investigation of the biochemical characteristics shows a significant change after adding 1.225% of tigecyclin per weight to PMMA-bone cement compared to customary products with gentamicin. Figure 2 
Discussion
The in vitro model of an osteomyelitis displays that the effectiveness of the novel antibiotic tigecyclin has to be ranked between gentamicin and rifampicin after incubation of 20 h and 40 h. The effectivness of rifampicin compared to gentamicin can be confirmed by in vitro and in vivo studies done in 2006 and 2009, in which a reduction of intracellular bacteria after treatment with rifampicin could be shown [34] . In 2008 and 2009 the synergistical effect of tigecyclin to rifampicin and gentamicin against S.aureus could be displayed in vivo and in vitro as a potential combined therapy against multiresistant bacteria [30, 35] . The synergistical effect of tigecyclin to gentamicin was confirmed in our study, whereas the additive effect of tigecyclin to rifampicin could not be shown. It is known that gentamicin has good activity in the extracellular space, whereas an additive effect to the effectiveness of tigecyclin cannot be assigned by our study. However, it remains uncertain if our results can be transferred to in vivo conditions as S. aureus quickly developes resistances [2] . It would be significant to search out if this has validity for tigecyclin as well. A combination of tigecyclin and rifampicin might be recommendable to prevent resistances. Yin et al.
show a complete bacterial eradication after a combined treatment with tigecyclin s.c. and rifampicin p.o. in an in vivo MRSA-osteomyelitis-model [36] . Furthermore, it has to be examined if higher doses of tigecyclin would on the one hand reduce the intracellular bacteria completly and on the other hand would induce the SCV-synthesis, which displays a handicap for antibiotic therapy. 1995 Henry and Galloway showed that PMMAbone cement loaded with antibiotics is an effective therapy for bone or soft tissue infections as it is possible to reach high antibiotic levels locally without their unwanted side effects [13] . Since 2003 gentamicin is added to PMMA-bone cement as the standard antibiotic substance with a broad antibacterial effectiveness, a low influence on biomechanical properties of bone cement and a good release out of bone cement [12] . Despite the study results it is doubtfull if tigecyclin is a potential alternative to gentamicin for the local use in bone cement.
Here the biomechanical investigation of tigecyclin shows a reduction of the stability of Palacos ®-bone cement compared to Palacos ®-bone cement loaded with gentamicin. It is known that bone cement loaded with gentamicin or rifampicin shows a good local effectiveness with reduction of implant-associated bacteria and reduction of biofilm synthesis [19, 21, 37] . Similar results are not yet exciting for tigecyclin [37] , which would be important to consider tigecyclin as an alternative to gentamicin in clinical daily routine. With the help of different models the good release of gentamicin out of bone cement could be displayed [12, 38] , but it is still uncertain if a constant release of gentamicin induces the synthesis of resistances or not [12] . Bone cement loaded with rifampicin reveals a bimodal elution kinetic with a fast, high concentrated initial release follwed by a slow, low concentrated release [18] . Comparable studies concerning the release of tigecyclin out of bone cement are missing. In actual studies there are only few resistances against tigecyclin listed and it is known as an effective therapy against MRSA-infections and biofilm associated bacteria [25, 26, 28, 39] . Furthermore tigecyclin reduces the expression of some important virulence factors of S. aureus [40] . 91% of multiresistant S. epidermidis are sensitive against tigecyclin [4] . Redvold et al. demonstrate the good bone absorption of tigecyclin after intravenous application [27] . On the other hand there is less clinical data exciting concerning this novel antibiotic substance associated with safety questions [41] . In addition Rose and Poppens demonstrate that tigecyclin does not reduce biofilm-associated S. aureus [42] .
Conclusions
In conclusion there is inconsistent result concerning tigecyclin. Tigecyclin shows effective intracellular activity against S. aureus with negative influence on the biomechanical stability of Palacos ®-bone cement. In total tigecyclin seems to be a possible therapy option or alternative in the systemic treatment of osteomyelitis because of its good intracellular effectiveness. The local application of tigecyclin has to be evaluated individually because of less biomechanical stability of bone cement.
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